Codexis Presents Pre-Clinical Data Highlighting Gene Therapy Programs at the ASGCT 25th Annual Meeting
Reimagine enzymes and transgenes as efficacious treatments for genetic disorders
Our PipelineThe ability of our technology to improve multiple protein properties in parallel led us to discover potential enzyme and gene therapy candidates optimized for specific therapeutic indications. Bringing together semi-rational library designs with application-focused high throughput screens allows us to generate large data sets, that with the aid of our bioinformatics software, yield therapeutic candidates that address needs in safety, efficacy, and manufacturability.
Our focus is on discovering safe and efficacious enzymes that are orally administered for function in the GI or that are administered as the transgene of a gene therapy for treatment of Inborn Errors of Metabolism (IEMs) and other metabolic diseases. Two of our therapeutic enzyme candidates are in Phase 1 clinical trials – CDX-6114 for potential treatment of phenylketonuria, and CDX-7108 for exocrine pancreatic insufficiency. CDX-6512 is currently in IND-enabling studies and has been granted orphan drug designation by the FDA.
We are committed to the advancement of therapeutic candidates with best-in-class efficacy through self-funded initiatives and in close collaboration with our valued partners.
Category | Program | Discovery | Pre-Clinical Research | IND-Enabling | Phase 1 | Partner |
---|---|---|---|---|---|---|
Oral Enzyme Therapies | CDX-6114 (Phenylketonuria) |
Discovery Phase complete
|
Pre-Clinical Research Phase complete
|
IND-Enabling Phase complete
|
Phase 1 Phase in progress
|
![]() |
CDX-7108 (Exocrine Pancreatic Insufficiency) |
Discovery Phase complete
|
Pre-Clinical Research Phase complete
|
IND-Enabling Phase complete
|
Phase 1 Phase in progress
|
![]() |
|
CDX-6512 (Homocystinuria) |
Discovery Phase complete
|
Pre-Clinical Research Phase complete
|
IND-Enabling Phase in progress
|
Phase 1 Phase not started
|
Wholly Owned | |
CDX-6210 (Maple Syrup Urine Disease) |
Discovery Phase complete
|
Pre-Clinical Research Phase in progress
|
IND-Enabling Phase not started
|
Phase 1 Phase not started
|
Wholly Owned | |
Gluten Management |
Discovery Phase in progress
|
Pre-Clinical Research Phase not started
|
IND-Enabling Phase not started
|
Phase 1 Phase not started
|
Wholly Owned | |
Undisclosed GI Program |
Discovery Phase complete
|
Pre-Clinical Research Phase in progress
|
IND-Enabling Phase not started
|
Phase 1 Phase not started
|
![]() |
|
Undisclosed GI Program |
Discovery Phase in progress
|
Pre-Clinical Research Phase not started
|
IND-Enabling Phase not started
|
Phase 1 Phase not started
|
![]() |
|
Gene Therapies | Fabry Disease Transgene |
Discovery Phase complete
|
Pre-Clinical Research Phase in progress
|
IND-Enabling Phase not started
|
Phase 1 Phase not started
|
![]() |
Pompe Disease Transgene |
Discovery Phase complete
|
Pre-Clinical Research Phase in progress
|
IND-Enabling Phase not started
|
Phase 1 Phase not started
|
![]() |
|
Blood Factor Disorder Transgene |
Discovery Phase complete
|
Pre-Clinical Research Phase in progress
|
IND-Enabling Phase not started
|
Phase 1 Phase not started
|
![]() |
|
Lysosomal Storage Disorder Transgene |
Discovery Phase in progress
|
Pre-Clinical Research Phase not started
|
IND-Enabling Phase not started
|
Phase 1 Phase not started
|
![]() |
|
Rare Disease Gene Therapy |
Discovery Phase in progress
|
Pre-Clinical Research Phase not started
|
IND-Enabling Phase not started
|
Phase 1 Phase not started
|
Wholly Owned | |
Gene Therapy Technology |
Discovery Phase in progress
|
Pre-Clinical Research Phase not started
|
IND-Enabling Phase not started
|
Phase 1 Phase not started
|
Wholly Owned |
1 Nestlé Health Science licensed CDX-6114 for world-wide development ; 2 Co-development by Nestlé Health Science and Codexis ; 3 World-wide rights licensed to Takeda
Marcus Rohovie, Sr. Scientist at Codexis, presented a poster at the ASGCT Annual Meeting that highlights the potential of engineered transgenes to offer improved efficacy of Recombinant Factor VIII (FVIII) therapies in patients with Hemophilia A. The CodeEvolver® technology platform was used to identify variants of a B-domain deleted FVIII (FVIII-BDD) with superior properties as compared to the wild-type enzyme.
View Poster